【首药控股:SY-12321胶囊单药在ALK阳性晚期实体瘤的临床试验申请获得批准】首药控股公告,公司于近日收到国家药品监督管理局核准签发的《药物临床试验批准通知书》,作为第四代ALK抑制剂候选药物,SY-12321胶囊单药在间变性淋巴瘤激酶阳性晚期实体瘤的临床试验申请获得批准。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.